ID   U3167MG
AC   CVCL_A1GF
DR   GEO; GSM2368452
DR   GEO; GSM2368634
DR   Wikidata; Q102115041
RX   PubMed=27974212;
RX   PubMed=28122246;
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): PubMed=27974212
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 10,13
ST   D18S51: 13,14
ST   D19S433: 13
ST   D21S11: 29,31
ST   D2S1338: 19,21
ST   D3S1358: 14,15
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 20,21
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   35Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 10-04-25; Version: 5
//
RX   PubMed=27974212; DOI=10.1016/j.celrep.2016.11.056;
RA   Segerman A., Niklasson M., Haglund C., Bergstrom T., Jarvius M.,
RA   Xie Y., Westermark A., Sonmez D., Hermansson A., Kastemar M.,
RA   Naimaie-Ali Z., Nyberg F., Berglund M., Sundstrom M., Hesselager G.,
RA   Uhrbom L., Gustafsson M., Larsson R., Fryknas M., Segerman B.,
RA   Westermark B.;
RT   "Clonal variation in drug and radiation response among
RT   glioma-initiating cells is linked to proneural-mesenchymal
RT   transition.";
RL   Cell Rep. 17:2994-3009(2016).
//
RX   PubMed=28122246; DOI=10.1016/j.celrep.2017.01.003;
RA   Jiang Y.-W., Marinescu V.D., Xie Y., Jarvius M., Maturi N.P.,
RA   Haglund C., Olofsson S., Lindberg N., Olofsson T., Leijonmarck C.,
RA   Hesselager G., Alafuzoff I., Fryknas M., Larsson R., Nelander S.,
RA   Uhrbom L.;
RT   "Glioblastoma cell malignancy and drug sensitivity are affected by the
RT   cell of origin.";
RL   Cell Rep. 18:977-990(2017).
//